_256_384.jpg)
News | May 14, 2025
Cipla reports FY25 PAT higher 28.4% at Rs. 5,273 Cr
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
The company reported 30.1% jump in Q4 FY25 PAT at Rs. 1,222 crore
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
Gelhaus has a proven track record of driving business growth
This outcome reflects Innoxel Lifesciences' ongoing commitment to maintaining the highest standards of quality, compliance, and regulatory excellence
30th Lab in Thyrocare’s expanding network to bring advanced, affordable diagnostics in Bihar and beyond
The Q1 2025 also witnessed a successful launch of Allegra D
Investment demonstrates confidence in America’s commitment to science and innovation
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
The 27 greenfield labs across the country ensure timely and accurate reporting
Subscribe To Our Newsletter & Stay Updated
